1. Antidiabetic Activity of Ergosterol from Pleurotus Ostreatus in KK-A y Mice with Spontaneous Type 2 Diabetes Mellitus.
- Author
-
Xiong M, Huang Y, Liu Y, Huang M, Song G, Ming Q, Ma X, Yang J, Deng S, Wen Y, Shen J, Liu QH, Zhao P, and Yang X
- Subjects
- Animals, Blood Glucose metabolism, Cell Line, Diabetes Mellitus, Experimental drug therapy, Diabetes Mellitus, Experimental metabolism, Diabetes Mellitus, Experimental pathology, Diabetes Mellitus, Type 2 metabolism, Diabetes Mellitus, Type 2 pathology, Glucose Transporter Type 4 metabolism, Male, Mice, Mutant Strains, Muscle Fibers, Skeletal drug effects, Muscle Fibers, Skeletal metabolism, Phosphorylation drug effects, Protein Kinase C metabolism, Proto-Oncogene Proteins c-akt metabolism, Rats, Diabetes Mellitus, Type 2 drug therapy, Ergosterol pharmacology, Hypoglycemic Agents pharmacology, Pleurotus chemistry
- Abstract
Scope: The number of people with diabetes is increasing rapidly in the world. In the present study, the hypoglycemic activity and potential mechanism of ergosterol (ERG), a phytosterol derived from the edible mushroom Pleurotus ostreatus are investigated in vitro and in vivo., Methods and Results: ERG is isolated from Pleurotus ostreatus and identified by NMR spectra. The effects of ERG on the glucose uptake, glucose transporter 4 (GLUT4) translocation, GLUT4 expression, and the phosphorylation of AMPK, Akt and PKC in L6 cells are evaluated. ERG enhances glucose uptake and displays a GLUT4 translocation activity with up-regulating GLUT4 expression and phosphorylation of Akt and PKC in L6 cells. In vivo, antidiabetic activity of ERG is examined. The phosphorylation of Akt and PKC in different tissues from KK-A
y mice is assessed. ERG significantly improves insulin resistance and blood lipid indices while reducing fasting blood glucose levels and protecting pancreas and liver in the mice. Moreover, the phosphorylation of Akt and PKC is increased in different tissues., Conclusion: The results suggest that ERG may be a potential hypoglycemic agent for the treatment of T2DM with the probable mechanism of stimulating GLUT4 translocation and expression modulated by the PI3K/Akt pathway and PKC pathway., (© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)- Published
- 2018
- Full Text
- View/download PDF